Moleculin Biotech Inc Quick Ratio (MBRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Moleculin Biotech Inc   (NASDAQ: MBRX)

Moleculin Biotech Inc 's Quick Ratio

MBRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.78 below Moleculin Biotech Inc average.

Within Major Pharmaceutical Preparations industry 371 other companies have achieved higher Quick Ratio than Moleculin Biotech Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1777, from total ranking in the first quarter 2026 at 2154.

Explain Quick Ratio?
How much Cash & cash equivalents MBRX´s has?
What are MBRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MBRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 17.69 % 15.46 % 27.9 % 1.59 % 37.71 %
Y / Y Cash & cash equivalent Change -3.9 % 33.71 % 107.53 % -28.73 % -30.32 %
Quick Ratio MRQ 0.78 1.3 1.3 1.18 0.96
MBRX's Total Ranking # 1777 # 2154 # 2081 # 2407 # 2236
Seq. Current Liabilities Change 16.97 % 16.17 % 20.63 % -28.19 % 14.75 %
Seq. Cash & cash equivalent Change -29.61 % 16.21 % 32.45 % -11.3 % -2.06 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 372
Healthcare Sector # 674
Overall Market # 2192


Quick Ratio Statistics
High Average Low
23.73 5.35 0.04
(Jun 30 2021)   (Dec 31 2015)




Financial Statements
Moleculin Biotech Inc 's Current Liabilities $ 9 Millions Visit MBRX's Balance sheet
Moleculin Biotech Inc 's Cash & cash equivalent $ 7 Millions Visit MBRX's Balance sheet
Source of MBRX's Sales Visit MBRX's Sales by Geography


Cumulative Moleculin Biotech Inc 's Quick Ratio

MBRX's Quick Ratio for the trailling 12 Months

MBRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 15.72 % 20.42 % 23.7 % 9.71 % 17.86 %
Y / Y Cash & cash equivalent TTM Growth 14.52 % 3.76 % -25.39 % -56.69 % -61.8 %
Quick Ratio TTM 1.11 1.18 1.13 1.02 1.12
Total Ranking TTM # 1142 # 1355 # 1098 # 1046 # 892
Seq. Current Liabilities TTM Growth 4.93 % 3.9 % 5.78 % 0.35 % 9.18 %
Seq. Cash & cash equivalent TTM Growth -0.88 % 8.43 % 17.52 % -9.33 % -10.2 %

Quick ratio ranking by company, industry and sector >> Back to MBRX Financial Strength Comparisons >> Go to Compare MBRX Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $9.31 millions, cumulative Quick Ratio decreased to 1.11 below the Moleculin Biotech Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Moleculin Biotech Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2737.

Explain Quick Ratio?
How much Cash & cash equivalents MBRX´s has?
What are MBRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 892
Within the Market # 1777


trailing twelve months Quick Ratio Statistics
High Average Low
20.51 5.81 1.02
(Dec 31 2021)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Ardelyx inc   2.13 $ 281.830  Millions$ 132.220  Millions
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions

Date modified: 2026-09-08T20:50:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.